World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
64
Citations
14247
World Ranking
2938
National Ranking
1381

Matthew F. Mescher publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Matthew F. Mescher sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 158 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Matthew F. Mescher D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Matthew F. Mescher sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 64 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Matthew F. Mescher is affiliated with the University of Minnesota in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with specific focus on Oncology and Immunology as subfields of study.

Mescher's work emphasizes topics such as CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses. These areas reflect an ongoing investigation into cellular therapies and immune system mechanisms relevant to cancer treatment.

Among recent publications, one notable paper is titled "Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity", published in 2020 in The Journal of Immunology. This paper has received citations indicating engagement from the scientific community. The venue The Journal of Immunology is also the most frequent publishing platform for their research.

Frequent coauthors collaborating with Mescher include:

  • Christopher Tucker
  • Jason S. Mitchell
  • Tijana Martinov
  • Brandon J. Burbach
  • Lalit K. Beura

This collaborative network supports work that integrates immunological approaches to cancer therapy and related biomarker studies. The coauthorship with these researchers suggests a multidisciplinary approach combining cellular immunology with translational oncology efforts.

There are no records of book publications or awards listed for Mescher up to this point. The scientist's profile is marked by a clear orientation toward research in immunotherapy with specific attention to therapeutic strategies targeting cancer and immune system regulation.

Best Publications

  • Inflammatory Cytokines Provide a Third Signal for Activation of Naive CD4 + and CD8 + T Cells

    Julie M. Curtsinger;Clint S. Schmidt;Anna Mondino;Debra C. Lins

  • Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation

    Julie M. Curtsinger;Javier O. Valenzuela;Pujya Agarwal;Debra Lins

  • Signals required for programming effector and memory development by CD8+ T cells.

    Matthew F. Mescher;Julie M Curtsinger;Pujya Agarwal;Kerry A. Casey

  • Inflammatory Cytokines as a Third Signal for T Cell Activation

    Julie M Curtsinger;Matthew F Mescher

  • Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells: Dissociating Proliferation and Development of Effector Function

    Julie M. Curtsinger;Debra C. Lins;Matthew F. Mescher

  • CD8 T Cell Clonal Expansion and Development of Effector Function Require Prolonged Exposure to Antigen, Costimulation, and Signal 3 Cytokine

    Julie M. Curtsinger;Christopher M. Johnson;Matthew F. Mescher

  • Purification and characterization of a prokaryotic glycoprotein from the cell envelope of Halobacterium salinarium.

    M F Mescher;J L Strominger

  • CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.

    Protul Shrikant;Alexander Khoruts;Matthew F Mescher

  • Programming for CD8 T Cell Memory Development Requires IL-12 or Type I IFN

    Zhengguo Xiao;Kerry A. Casey;Stephen C. Jameson;Julie M. Curtsinger

  • The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells.

    Javier Valenzuela;Clint Schmidt;Clint Schmidt;Matthew F Mescher

  • Gene Regulation and Chromatin Remodeling by IL-12 and Type I IFN in Programming for CD8 T Cell Effector Function and Memory

    Pujya Agarwal;Arvind Raghavan;Sarada L. Nandiwada;Julie M. Curtsinger

  • Cytotoxic T lymphocyte mediated lysis without release of serine esterase.

    Hanne L. Ostergaard;Kevin P. Kane;Matthew F. Mescher;William R. Clark

  • CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen.

    Julie M. Curtsinger;Debra C. Lins;Matthew F. Mescher

  • Actin-containing matrix associated with the plasma membrane of murine tumour and lymphoid cells.

    Matthew F. Mescher;Mimi J. L. Jose;Steven P. Balk

  • The Autoimmunity-Associated Gene PTPN22 Potentiates Toll-like Receptor-Driven, Type 1 Interferon-Dependent Immunity

    Yaya Wang;Iftach Shaked;Stephanie M. Stanford;Wenbo Zhou

  • CD8+ T Cells Become Nonresponsive (Anergic) Following Activation in the Presence of Costimulation

    Matthew J. Deeths;Ross M. Kedl;Matthew F. Mescher

  • Alloreactive T cells discriminate among a diverse set of endogenous peptides.

    William R. Heath;Kevin P. Kane;Matthew F. Mescher;Linda A. Sherman

  • Adjuvant Effect of IL-12: Conversion of Peptide Antigen Administration from Tolerizing to Immunizing for CD8+ T Cells In Vivo

    Clint S. Schmidt;Matthew F. Mescher

  • Control of Syngeneic Tumor Growth by Activation of CD8+ T Cells: Efficacy Is Limited by Migration Away from the Site and Induction of Nonresponsiveness

    Protul Shrikant;Matthew F. Mescher

  • Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12.

    Clint S. Schmidt;Matthew F. Mescher

Frequent Co-Authors

Steven J. Burakoff
Steven J. Burakoff Icahn School of Medicine at Mount Sinai
Zhengguo Xiao
Zhengguo Xiao University of Science and Technology of China
Linda A. Sherman
Linda A. Sherman Scripps Research Institute
Steven P. Balk
Steven P. Balk Beth Israel Deaconess Medical Center
Jaime F. Modiano
Jaime F. Modiano University of Minnesota
Yoji Shimizu
Yoji Shimizu University of Minnesota
Jack L. Strominger
Jack L. Strominger Harvard University
Stephen C. Jameson
Stephen C. Jameson University of Minnesota
Protul Shrikant
Protul Shrikant Mayo Clinic
Baruj Benacerraf
Baruj Benacerraf Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens doors to various healthcare and research careers. For those interested in clinical roles with a focus on patient care, exploring nursing programs can be a valuable step. Many students transition into nursing through fast-track options like accelerated nurse practitioner program, which allows individuals to become advanced practitioners efficiently.

If you are starting without a nursing background, the best online rn programs for non nurses provide flexible learning paths to obtain a registered nurse license. These programs accommodate busy schedules and often integrate clinical experiences tailored for immunology applications.

For quicker entry into the nursing profession, accelerated nursing programs are available that reduce the time needed to earn a Bachelor of Science in Nursing. These are designed for motivated learners aiming to build a foundation in healthcare science and immunology-related fields.

Additionally, if seeking an entry-level healthcare role, lpn programs easy to get into offer accessible pathways. Licensed Practical Nurses play crucial roles supporting immunologists and healthcare teams, making this an excellent starting point for hands-on experience.

Best Scientists Citing Matthew F. Mescher

Trending Scientists

Recently Published Articles